Table 3. Titanocref Altered mRNAs in Caki-1 Kidney Cancer Cellsa.
| gene symbol | description | fold change | P-value |
|---|---|---|---|
| HMOX1 | heme oxygenase 1 | 56.3 | 1.39 × 10–12 |
| HSPA6 | heat shock 70 kDa protein 6 (HSP70B) | 5.9 | 1.45 × 10–05 |
| HSPA1A | heat shock 70 kDa protein 1A | 5.05 | 1.13 × 10–06 |
| HSPA1B | heat shock 70 kDa protein 1B | 4.79 | 3.48 × 10–06 |
| KIF5B | Kinesin-1 heavy chain | 2.8 | 0.013 |
| DUSP5 | dual specificity phosphatase 5 | 2.73 | 2.11 × 10–08 |
| LRRC28 | Leucine rich repeat containing 28 | 2.49 | 0.0323 |
| DUSP1 | dual specificity phosphatase 1 | 2.43 | 1.04 × 10–05 |
| FAM151B | family with sequence similarity 151 member B | 2.4 | 0.0139 |
| BAG3 | BCL2-associated athanogene 3 | 2.25 | 0.0005 |
| ZFAND2A | zinc finger, AN1-type domain 2A | 2.15 | 5.90 × 10–07 |
| DNAJB1 | DnaJ (Hsp40) homologue, subfamily B, member 1 | 2.09 | 7.42 × 10–05 |
| MAATS1 | MYCBP-associated, testis expressed 1 | –2.01 | 0.0153 |
| KLRC4 | killer cell lectin-like receptor subfamily C, member 4 | –2.12 | 0.0006 |
| MYRFL | Myelin regulatory factor-like | –2.35 | 0.0045 |
a
12 up-regulated and 3 down-regulated differentially expressed genes list after Titanocref treatment. Transcripts from nontreated and Titanocref treated were aligned and considered as differentially expressed genes with at least 2-fold change difference and p < 0.05.